TOKYO (Reuters) - Takeda Pharmaceutical shares sank 5 percent early on Thursday, a day after Japan's largest drugmaker said it was considering a bid for London-listed rare disease specialist Shire that could top $40 billion.
Shares in Takeda fell more than 5 percent in early morning trade, sharply underperforming the broader Tokyo market <.TOPX>, which was slightly higher.
Takeda said on Wednesday it was "at a preliminary and exploratory stage" of considering a bid that could spark another takeover battle in the deal-hungry pharma industry. Shire's shares ended 15.7 percent higher, valuing the group at around 32 billion pounds ($45 billion).
(Reporting by Minami Funakoshi; Editing by Chang-Ran Kim)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app